US · NUTX · MEDICAL - CARE FACILITIES
Nutex Health, Inc. (NUTX) intrinsic value and stock valuation
$162.64as of 2026-11-21 · Mkt cap 1.08B
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
Nutex Health, Inc. DCF and intrinsic value
InvestorsCraft values NUTX with the Chepakovich two-stage DCF model — currently rated fairly valued. How the model works · Run your own DCF prefilled from NUTX’s statements →
Nutex Health, Inc. Graham Number
Graham Number: $129.10d — the price is above the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →
How the business is doing
Fiscal 2009–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $875.3M | $480M | $247.7M | $219.3M | $331.5M |
| Operating income | $275.6M | $130.6M | -$-31.77M | -$-406.6M | $170.3M |
| Net income | $70.8M | $52.2M | -$-45.79M | -$-424.78M | $132.6M |
| EPSd | $10.5M | $10.2M | -$-10.38M | -$-100.42M | $33.6M |
| Operating cash flow | $248.1M | $23.2M | $1.26M | $50.6M | $173.4M |
| Capital expenditure | -$-2.53M | -$-2.3M | -$-9.5M | -$-14.63M | -$-36.93M |
| Free cash flow | $245.6M | $20.9M | -$-8.24M | $36M | $136.5M |
| Total assets | $918.5M | $655.3M | $398.3M | $431.8M | $394.7M |
| Total debt | $351.4M | $340.3M | $275.8M | $267.2M | $178.6M |
| Net debt | $165.8M | $296.7M | $253.8M | $233M | $142.4M |
| Total equity | $423.4M | $201.9M | $79.1M | $120.3M | $191.6M |
| Cash and short-term investments | $185.6M | $43.6M | $22M | $34.3M | $36.1M |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $875.3M | $480M | $247.7M | $219.3M | $331.5M |
| Cost of revenue | $431M | $283.7M | $212.9M | $203.9M | $152.3M |
| Gross profit | $444.3M | $196.3M | $34.8M | $15.4M | $179.3M |
| Research and development expenses | $0.00 | $0.00 | $0.00 | $0.00 | $290K |
| Selling, general and administrative expenses | $168.7M | $58.6M | $36.1M | $20M | $5.46M |
| Other expenses | $0.00 | $7.08M | $30.5M | $402M | $3.27M |
| Operating expenses | $168.7M | $65.6M | $66.6M | $422M | $9.02M |
| Cost and expenses | $599.6M | $349.3M | $279.4M | $625.9M | $161.3M |
| Interest income | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Interest expense | $22.2M | $19.9M | $16.3M | $12.5M | $6.2M |
| Depreciation and amortization | $20.5M | $19M | $17.6M | $13.1M | $7.76M |
| Ebitda | $287.5M | $148.7M | -$-14.58M | -$-394.03M | $183.5M |
| Operating income | $275.6M | $130.6M | -$-31.77M | -$-406.6M | $170.3M |
| Total other income/expenses, net | -$-30.84M | -$-20.87M | -$-16.72M | -$-13.05M | -$-770K |
| Income before tax | $244.8M | $109.8M | -$-48.49M | -$-419.65M | $169.5M |
| Income tax expense | $64.4M | $14.5M | -$-5.07M | $13.1M | $970K |
| Net income | $70.8M | $52.2M | -$-45.79M | -$-424.78M | $132.6M |
| Weighted average shares outstanding | $6.36M | $5.1M | $4.41M | $4.23M | $4.02M |
| Weighted average diluted shares outstanding | $6.76M | $5.1M | $4.41M | $4.23M | $3.95M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $185.6M | $43.6M | $22M | $34.3M | $36.1M |
| Net receivables | $325.4M | $236.1M | $62.8M | $58.3M | $114.8M |
| Inventory | $2.87M | $2.85M | $3.39M | $3.53M | $2.81M |
| Total current assets | $538.8M | $292.5M | $90.9M | $98M | $154M |
| Property, plant and equipment, net | $343.9M | $324.7M | $269.4M | $295.2M | $238.4M |
| Goodwill and intangible assets | $35.2M | $29.5M | $37.6M | $38.2M | $1.82M |
| Long-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current assets | $379.7M | $362.8M | $307.4M | $333.8M | $240.6M |
| Total assets | $918.5M | $655.3M | $398.3M | $431.8M | $394.7M |
| Accounts payable | $49M | $14M | $25.3M | $23.9M | $17.7M |
| Short-term debt | $23.3M | $27.7M | $20.1M | $21.1M | $13.2M |
| Deferred revenue | $0.00 | $0.00 | $0.00 | $0.00 | $170K |
| Total current liabilities | $157.9M | $140.9M | $58.3M | $54.9M | $37.7M |
| Long-term debt | $328.1M | $312.6M | $255.7M | $246.1M | $165.4M |
| Deferred revenue, non-current | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current liabilities | $337.2M | $312.6M | $260.8M | $256.6M | $165.4M |
| Capital lease obligations | $308.1M | $299.9M | $235.3M | $229M | $89.5M |
| Total liabilities | $495.1M | $453.4M | $319.1M | $311.4M | $203.1M |
| Common stock | $10K | $10K | $680K | $650K | $590K |
| Retained earnings | -$-286.19M | -$-356.89M | -$-409.07M | -$-363.29M | $102.3M |
| Accumulated other comprehensive income (loss) | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total equity | $423.4M | $201.9M | $79.1M | $120.3M | $191.6M |
| Total investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $351.4M | $340.3M | $275.8M | $267.2M | $178.6M |
| Net debt | $165.8M | $296.7M | $253.8M | $233M | $142.4M |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | $180.4M | $95.3M | -$-43.42M | -$-432.74M | $168.5M |
| Depreciation and amortization | $20.5M | $19M | $17.6M | $13.1M | $7.66M |
| Stock-based compensation | $117M | $16.6M | $2.84M | $190K | $0.00 |
| Change in working capital | -$-87.74M | -$-104.4M | -$-1.66M | $64.3M | $2.75M |
| Accounts receivable | -$-89.32M | -$-173.41M | -$-4.58M | $58.1M | -$-6.62M |
| Inventory | -$-20K | $540K | $140K | -$-720K | -$-1.09M |
| Accounts payable | $37.9M | -$-10.72M | -$-2.25M | $9.69M | $6.27M |
| Net cash provided by operating activities | $248.1M | $23.2M | $1.26M | $50.6M | $173.4M |
| Investments in property, plant and equipment | -$-2.53M | -$-2.3M | -$-9.5M | -$-14.63M | -$-36.93M |
| Acquisitions, net | $0.00 | -$-360K | -$-1.74M | $10.3M | -$-50K |
| Net cash used for investing activities | -$-5.24M | -$-2.67M | -$-11.24M | -$-4.34M | -$-36.98M |
| Common stock issued | $0.00 | $9.2M | $0.00 | $4.76M | $0.00 |
| Common stock repurchased | -$-5M | $0.00 | $0.00 | $0.00 | $0.00 |
| Dividends paid | -$-74.28M | -$-6.44M | -$-5.21M | -$-51.23M | -$-144.34M |
| Net cash used for financing activities | -$-97.95M | $1.09M | -$-2.27M | -$-48.13M | -$-125.85M |
| Net change in cash | $145.2M | $21.6M | -$-12.25M | -$-1.86M | $10.6M |
| Cash at end of period | $185.9M | $43.6M | $22M | $34.3M | $36.1M |
| Operating cash flow | $248.1M | $23.2M | $1.26M | $50.6M | $173.4M |
| Capital expenditure | -$-2.53M | -$-2.3M | -$-9.5M | -$-14.63M | -$-36.93M |
| Free cash flow | $245.6M | $20.9M | -$-8.24M | $36M | $136.5M |
Line items
Line items
Line items
About Nutex Health, Inc.
Nutex Health, Inc. functions as a technology-powered enterprise delivering healthcare services, structured into two key segments: its Hospital division and its Population Health Management division. The Hospital division is tasked with developing and overseeing various healthcare models, encompassing micro-hospitals, specialized medical centers, and hospital outpatient facilities. This segment currently owns and operates 21 locations spanning eight different states. Meanwhile, the Population Health Management division establishes and manages provider networks, such as independent physician associations. Additionally, its management services organizations furnish administrative, operational, and support assistance to its associated hospitals and physician groups. A proprietary, cloud-based technology platform within this division is crucial; it aggregates patient and provider data from multiple information systems, settings, and sources to construct a holistic view, thereby enabling more effective care delivery. The company maintains its corporate headquarters in Houston, Texas.
- CEO
- Thomas T. Vo
- Employees
- 944
- Beta
- 1.97
Explore
Frequently asked questions
What is the intrinsic value of Nutex Health, Inc. (NUTX)?
Nutex Health, Inc. (NUTX) is currently fairly valued based on the InvestorsCraft IC model — IC value is within 20% of the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.
Is NUTX undervalued?
NUTX trades at a price of $162.64 (Nov 21, 2026): fairly valued — IC value is within 20% of the price.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.